Advances in the use of MOFs for Cancer Diagnosis and Treatment: An Overview

Author(s): Marina P. Abuçafy, Bruna L. da Silva, João A. Oshiro-Junior, Eloisa B. Manaia, Bruna G. Chiari-Andréo, Renan A. M. Armando, Regina C. G. Frem, Leila A. Chiavacci*

Journal Name: Current Pharmaceutical Design

Volume 26 , Issue 33 , 2020

Become EABM
Become Reviewer

Abstract:

Nanoparticles as drug delivery systems and diagnostic agents have gained much attention in recent years, especially for cancer treatment. Nanocarriers improve the therapeutic efficiency and bioavailability of antitumor drugs, besides providing preferential accumulation at the target site. Among different types of nanocarriers for drug delivery assays, metal-organic frameworks (MOFs) have attracted increasing interest in the academic community. MOFs are an emerging class of coordination polymers constructed of metal nodes or clusters and organic linkers that show the capacity to combine a porous structure with high drug loading through distinct kinds of interactions, overcoming the limitations of traditional drug carriers explored up to date. Despite the rational design and synthesis of MOFs, structural aspects and some applications of these materials like gas adsorption have already been comprehensively described in recent years; it is time to demonstrate their potential applications in biomedicine. In this context, MOFs can be used as drug delivery systems and theranostic platforms due to their ability to release drugs and accommodate imaging agents. This review describes the intrinsic characteristics of nanocarriers used in cancer therapy and highlights the latest advances in MOFs as anticancer drug delivery systems and diagnostic agents.

Keywords: Metal-organic frameworks, nanocarriers, drug delivery, cancer diagnosis, cancer therapy, cancer theranostics.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 26
ISSUE: 33
Year: 2020
Page: [4174 - 4184]
Pages: 11
DOI: 10.2174/1381612826666200406153949
Price: $65

Article Metrics

PDF: 19